To demonstrate that the early addition of Pentaglobin to the best available antimicrobial
therapy is able to reduce mortality and improve survival in neutropenic febrile acute
leukemia or allo- Hematopoietic stem cell transplantation (HSCT) patients colonized by
carbapenem-resistant Enterobacteriaceae or by any Pseudomonas aeruginosa.